世界の神経変性疾患市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neurodegenerative Disease Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4087
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、90ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、神経変性疾患のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（NMDA、SSRI、ドーパミン阻害剤）、用途別市場規模（パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、アルツハイマー病）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・神経変性疾患の市場動向
・企業の競争状況、市場シェア
・神経変性疾患の種類別市場規模（NMDA、SSRI、ドーパミン阻害剤）
・神経変性疾患の用途別市場規模（パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、アルツハイマー病）
・神経変性疾患の北米市場規模2016-2027（アメリカ、カナダ）
・神経変性疾患のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・神経変性疾患のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・神経変性疾患の中南米市場規模2016-2027（メキシコ、ブラジル）
・神経変性疾患の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Novartis、Pfizer、Merck Serono、Biogen Idec、TEVA、UCB、Boehringer Ingelheim、Sanofi、GlaxoSmithKline）
・結論

Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss.

Market Analysis and Insights: Global Neurodegenerative Disease Market
The global Neurodegenerative Disease market size is projected to reach US$ 8704 million by 2026, from US$ 7003.2 million in 2019, at a CAGR of 3.1% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Disease market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Disease market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Disease market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Disease market.

Global Neurodegenerative Disease Scope and Market Size
Neurodegenerative Disease market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
NMDA
SSRIs
Dopamine Inhibitors

Segment by Application
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neurodegenerative Disease Market Perspective (2016-2027)
2.2 Neurodegenerative Disease Growth Trends by Regions
2.2.1 Neurodegenerative Disease Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurodegenerative Disease Historic Market Share by Regions (2016-2021)
2.2.3 Neurodegenerative Disease Forecasted Market Size by Regions (2022-2027)
2.3 Neurodegenerative Disease Industry Dynamic
2.3.1 Neurodegenerative Disease Market Trends
2.3.2 Neurodegenerative Disease Market Drivers
2.3.3 Neurodegenerative Disease Market Challenges
2.3.4 Neurodegenerative Disease Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disease Players by Revenue
3.1.1 Global Top Neurodegenerative Disease Players by Revenue (2016-2021)
3.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2016-2021)
3.2 Global Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disease Revenue
3.4 Global Neurodegenerative Disease Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Revenue in 2020
3.5 Neurodegenerative Disease Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disease Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disease Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Disease Breakdown Data by Type
4.1 Global Neurodegenerative Disease Historic Market Size by Type (2016-2021)
4.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2022-2027)

5 Neurodegenerative Disease Breakdown Data by Application
5.1 Global Neurodegenerative Disease Historic Market Size by Application (2016-2021)
5.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neurodegenerative Disease Market Size (2016-2027)
6.2 North America Neurodegenerative Disease Market Size by Type
6.2.1 North America Neurodegenerative Disease Market Size by Type (2016-2021)
6.2.2 North America Neurodegenerative Disease Market Size by Type (2022-2027)
6.2.3 North America Neurodegenerative Disease Market Size by Type (2016-2027)
6.3 North America Neurodegenerative Disease Market Size by Application
6.3.1 North America Neurodegenerative Disease Market Size by Application (2016-2021)
6.3.2 North America Neurodegenerative Disease Market Size by Application (2022-2027)
6.3.3 North America Neurodegenerative Disease Market Size by Application (2016-2027)
6.4 North America Neurodegenerative Disease Market Size by Country
6.4.1 North America Neurodegenerative Disease Market Size by Country (2016-2021)
6.4.2 North America Neurodegenerative Disease Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Neurodegenerative Disease Market Size (2016-2027)
7.2 Europe Neurodegenerative Disease Market Size by Type
7.2.1 Europe Neurodegenerative Disease Market Size by Type (2016-2021)
7.2.2 Europe Neurodegenerative Disease Market Size by Type (2022-2027)
7.2.3 Europe Neurodegenerative Disease Market Size by Type (2016-2027)
7.3 Europe Neurodegenerative Disease Market Size by Application
7.3.1 Europe Neurodegenerative Disease Market Size by Application (2016-2021)
7.3.2 Europe Neurodegenerative Disease Market Size by Application (2022-2027)
7.3.3 Europe Neurodegenerative Disease Market Size by Application (2016-2027)
7.4 Europe Neurodegenerative Disease Market Size by Country
7.4.1 Europe Neurodegenerative Disease Market Size by Country (2016-2021)
7.4.2 Europe Neurodegenerative Disease Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Market Size (2016-2027)
8.2 Asia-Pacific Neurodegenerative Disease Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Disease Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurodegenerative Disease Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurodegenerative Disease Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurodegenerative Disease Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Disease Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurodegenerative Disease Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurodegenerative Disease Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurodegenerative Disease Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Disease Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurodegenerative Disease Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neurodegenerative Disease Market Size (2016-2027)
9.2 Latin America Neurodegenerative Disease Market Size by Type
9.2.1 Latin America Neurodegenerative Disease Market Size by Type (2016-2021)
9.2.2 Latin America Neurodegenerative Disease Market Size by Type (2022-2027)
9.2.3 Latin America Neurodegenerative Disease Market Size by Type (2016-2027)
9.3 Latin America Neurodegenerative Disease Market Size by Application
9.3.1 Latin America Neurodegenerative Disease Market Size by Application (2016-2021)
9.3.2 Latin America Neurodegenerative Disease Market Size by Application (2022-2027)
9.3.3 Latin America Neurodegenerative Disease Market Size by Application (2016-2027)
9.4 Latin America Neurodegenerative Disease Market Size by Country
9.4.1 Latin America Neurodegenerative Disease Market Size by Country (2016-2021)
9.4.2 Latin America Neurodegenerative Disease Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Market Size (2016-2027)
10.2 Middle East & Africa Neurodegenerative Disease Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Disease Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurodegenerative Disease Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurodegenerative Disease Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurodegenerative Disease Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Disease Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurodegenerative Disease Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurodegenerative Disease Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurodegenerative Disease Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Disease Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurodegenerative Disease Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Neurodegenerative Disease Introduction
11.1.4 Novartis Revenue in Neurodegenerative Disease Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Disease Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Disease Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Merck Serono
11.3.1 Merck Serono Company Details
11.3.2 Merck Serono Business Overview
11.3.3 Merck Serono Neurodegenerative Disease Introduction
11.3.4 Merck Serono Revenue in Neurodegenerative Disease Business (2016-2021)
11.3.5 Merck Serono Recent Development
11.4 Biogen Idec
11.4.1 Biogen Idec Company Details
11.4.2 Biogen Idec Business Overview
11.4.3 Biogen Idec Neurodegenerative Disease Introduction
11.4.4 Biogen Idec Revenue in Neurodegenerative Disease Business (2016-2021)
11.4.5 Biogen Idec Recent Development
11.5 TEVA
11.5.1 TEVA Company Details
11.5.2 TEVA Business Overview
11.5.3 TEVA Neurodegenerative Disease Introduction
11.5.4 TEVA Revenue in Neurodegenerative Disease Business (2016-2021)
11.5.5 TEVA Recent Development
11.6 UCB
11.6.1 UCB Company Details
11.6.2 UCB Business Overview
11.6.3 UCB Neurodegenerative Disease Introduction
11.6.4 UCB Revenue in Neurodegenerative Disease Business (2016-2021)
11.6.5 UCB Recent Development
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Details
11.7.2 Boehringer Ingelheim Business Overview
11.7.3 Boehringer Ingelheim Neurodegenerative Disease Introduction
11.7.4 Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2016-2021)
11.7.5 Boehringer Ingelheim Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Neurodegenerative Disease Introduction
11.8.4 Sanofi Revenue in Neurodegenerative Disease Business (2016-2021)
11.8.5 Sanofi Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Neurodegenerative Disease Introduction
11.9.4 GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2016-2021)
11.9.5 GlaxoSmithKline Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neurodegenerative Disease Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of NMDA
Table 3. Key Players of SSRIs
Table 4. Key Players of Dopamine Inhibitors
Table 5. Global Neurodegenerative Disease Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Neurodegenerative Disease Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neurodegenerative Disease Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Neurodegenerative Disease Market Share by Regions (2016-2021)
Table 9. Global Neurodegenerative Disease Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Neurodegenerative Disease Market Share by Regions (2022-2027)
Table 11. Neurodegenerative Disease Market Trends
Table 12. Neurodegenerative Disease Market Drivers
Table 13. Neurodegenerative Disease Market Challenges
Table 14. Neurodegenerative Disease Market Restraints
Table 15. Global Neurodegenerative Disease Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Neurodegenerative Disease Market Share by Players (2016-2021)
Table 17. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disease as of 2020)
Table 18. Ranking of Global Top Neurodegenerative Disease Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Neurodegenerative Disease Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neurodegenerative Disease Product Solution and Service
Table 22. Date of Enter into Neurodegenerative Disease Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Neurodegenerative Disease Revenue Market Share by Type (2016-2021)
Table 26. Global Neurodegenerative Disease Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Neurodegenerative Disease Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Neurodegenerative Disease Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Neurodegenerative Disease Revenue Market Share by Application (2016-2021)
Table 30. Global Neurodegenerative Disease Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Neurodegenerative Disease Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neurodegenerative Disease Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Neurodegenerative Disease Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
Table 62. Novartis Company Details
Table 63. Novartis Business Overview
Table 64. Novartis Neurodegenerative Disease Product
Table 65. Novartis Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 66. Novartis Recent Development
Table 67. Pfizer Company Details
Table 68. Pfizer Business Overview
Table 69. Pfizer Neurodegenerative Disease Product
Table 70. Pfizer Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Merck Serono Company Details
Table 73. Merck Serono Business Overview
Table 74. Merck Serono Neurodegenerative Disease Product
Table 75. Merck Serono Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 76. Merck Serono Recent Development
Table 77. Biogen Idec Company Details
Table 78. Biogen Idec Business Overview
Table 79. Biogen Idec Neurodegenerative Disease Product
Table 80. Biogen Idec Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 81. Biogen Idec Recent Development
Table 82. TEVA Company Details
Table 83. TEVA Business Overview
Table 84. TEVA Neurodegenerative Disease Product
Table 85. TEVA Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 86. TEVA Recent Development
Table 87. UCB Company Details
Table 88. UCB Business Overview
Table 89. UCB Neurodegenerative Disease Product
Table 90. UCB Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 91. UCB Recent Development
Table 92. Boehringer Ingelheim Company Details
Table 93. Boehringer Ingelheim Business Overview
Table 94. Boehringer Ingelheim Neurodegenerative Disease Product
Table 95. Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 96. Boehringer Ingelheim Recent Development
Table 97. Sanofi Company Details
Table 98. Sanofi Business Overview
Table 99. Sanofi Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 100. Sanofi Recent Development
Table 101. GlaxoSmithKline Company Details
Table 102. GlaxoSmithKline Business Overview
Table 103. GlaxoSmithKline Neurodegenerative Disease Product
Table 104. GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 105. GlaxoSmithKline Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disease Market Share by Type: 2020 VS 2027
Figure 2. NMDA Features
Figure 3. SSRIs Features
Figure 4. Dopamine Inhibitors Features
Figure 5. Global Neurodegenerative Disease Market Share by Application: 2020 VS 2027
Figure 6. Parkinson’s Disease Case Studies
Figure 7. Huntington Disease Case Studies
Figure 8. Amyotrophic Lateral Sclerosis Case Studies
Figure 9. Alzheimer’s Disease Case Studies
Figure 10. Neurodegenerative Disease Report Years Considered
Figure 11. Global Neurodegenerative Disease Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Neurodegenerative Disease Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Neurodegenerative Disease Market Share by Regions: 2020 VS 2027
Figure 14. Global Neurodegenerative Disease Market Share by Regions (2022-2027)
Figure 15. Global Neurodegenerative Disease Market Share by Players in 2020
Figure 16. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disease as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Revenue in 2020
Figure 18. Global Neurodegenerative Disease Revenue Market Share by Type (2016-2021)
Figure 19. Global Neurodegenerative Disease Revenue Market Share by Type (2022-2027)
Figure 20. North America Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 22. North America Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 23. North America Neurodegenerative Disease Market Share by Country (2016-2027)
Figure 24. United States Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 28. Europe Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 29. Europe Neurodegenerative Disease Market Share by Country (2016-2027)
Figure 30. Germany Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Neurodegenerative Disease Market Share by Region (2016-2027)
Figure 40. China Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 48. Latin America Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 49. Latin America Neurodegenerative Disease Market Share by Country (2016-2027)
Figure 50. Mexico Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Neurodegenerative Disease Market Share by Country (2016-2027)
Figure 56. Turkey Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Novartis Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 61. Merck Serono Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 62. Biogen Idec Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 63. TEVA Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 64. UCB Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 65. Boehringer Ingelheim Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 66. Sanofi Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 67. GlaxoSmithKline Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

以下、関連資料のご紹介

世界の神経変性疾患治療薬市場規模・現状・予測（2021年-2027年）

Global Neurodegenerative Diseases Drug Market Size, Status and Forecast 2021-2027
QYR2104Z4088 2021年4月 92Pages
QYResearch社発行の本調査資料では、神経変性疾患治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドーパミン作動薬、その他）、用途別市場規模（多発性硬化症、パーキンソン病、アル...

世界の神経変性疾患市場 2021：企業別、地域別、種類・用途別

Global Neurodegenerative Disease Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z09916 2021年4月 107Pages
当調査資料では、神経変性疾患のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。神経変性疾患の種類別市場規模（NMDA、SSRI、ドーパミン阻害剤）、用途別市場規模（パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、アルツハイマー病）、地域別市場規模（北...

世界の神経変性治療薬市場 2021：企業別、地域別、種類・用途別

Global Neurodegenerative Drugs Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-2104Z09917 2021年4月 100Pages
当調査資料では、神経変性治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。神経変性治療薬の種類別市場規模（NMDA、SSRI、ドーパミン阻害剤）、用途別市場規模（パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、アルツハイマー病）、地域別市場規模...

世界のサンドホフ病治療市場規模・現状・予測（2021年-2027年）

Global Sandhoff Disease Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z5108 2021年4月 92Pages
QYResearch社発行の本調査資料では、サンドホフ病治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ALD-601、CCP-010、DUOC-01、MTf-HEXB、その他）、用途別市場規模（クリニック、病院、その他）、主要地域別市場規...

世界のクラッベ病治療市場規模・現状・予測（2021年-2027年）

Global Krabbe Disease Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3334 2021年4月 92Pages
QYResearch社発行の本調査資料では、クラッベ病治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗けいれん薬、筋弛緩薬、HSCT（造血幹細胞移植）、その他）、用途別市場規模（病院、ASC）、主要地域別市場規模（北米、アメリカ、ヨーロッ...

世界の髄膜炎菌性疾患治療市場規模・現状・予測（2021年-2027年）

Global Meningococcal Disease Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3701 2021年4月 97Pages
QYResearch社発行の本調査資料では、髄膜炎菌性疾患治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗生物質、ワクチン）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中...

世界のニューカッスル病治療市場規模・現状・予測（2021年-2027年）

Global Newcastle Disease Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4115 2021年4月 93Pages
QYResearch社発行の本調査資料では、ニューカッスル病治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（弱毒生ワクチン、不活化ワクチン、結合型ワクチン）、用途別市場規模（獣医病院、獣医クリニック、獣医研究機関、ドラッグストア、その他）、...

世界の炎症性腸疾患治療市場規模・現状・予測（2021年-2027年）

Global Inflammatory Bowel Disease Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z3161 2021年4月 94Pages
QYResearch社発行の本調査資料では、炎症性腸疾患治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗炎症生物製剤、非ステロイド性抗炎症薬（NSAID）、コルチコステロイド）、用途別市場規模（病院用、家庭用）、主要地域別市場規模（北米、...

世界のクッシング病治療市場規模・現状・予測（2021年-2027年）

Global Cushing’s Disease Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1677 2021年4月 93Pages
QYResearch社発行の本調査資料では、クッシング病治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ケトコナゾール、ミトタン、アミノグルテチミド、メチラポン、ミフェプリストン、エトミデート、パシレオチド）、用途別市場規模（病院薬局、小売...

世界のアルツハイマー病治療市場規模・現状・予測（2021年-2027年）

Global Alzheimers Disease Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z0279 2021年4月 98Pages
QYResearch社発行の本調査資料では、アルツハイマー病治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（バイオマーカー、コリンエステラーゼ阻害剤、NMDA受容体拮抗薬）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメ...

世界の神経変性疾患市場 2021：企業別、地域別、種類・用途別 The Neurodegenerative Disease market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regul…
世界の筋萎縮性側索硬化症（ルーゲーリック病）治療市場規模・現状・予測（2021年-2027年） Amyotrophic Lateral Sclerosis (ALS) is a neurological disease that affects nerve cells in the brain and spinal cords which controls the activity of voluntary muscles. It is also termed as Lou Gehrig’s disease. There are several causes behind ALS which includes gene mutation, disorganized immune resp…
世界の筋萎縮性側索硬化症（ルーゲーリック病）治療市場規模・現状・予測（2021年-2027年） Amyotrophic Lateral Sclerosis (ALS) is a neurological disease that affects nerve cells in the brain and spinal cords which controls the activity of voluntary muscles. It is also termed as Lou Gehrig’s disease. There are several causes behind ALS which includes gene mutation, disorganized immune resp…
世界の神経変性治療薬市場 2021：企業別、地域別、種類・用途別 The Neurodegenerative Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
世界のパーキンソン病市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Parkinson's Disease Market The global Parkinson's Disease market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report mak…